Priority Date: 31.10.08 (US 20080197869P)

P2X3 receptor antagonists for treatment of pain

  • Application ID: EP14185280
  • Status: GRANT OF PATENT INTENDED

Applicant

Technology company logo small
Technology Company

Attorneys

no operation time available
7 offices
Technology Company
no operation time available
4 offices
Technology Company
no operation time available
4 offices
Technology Company
no operation time available
4 offices
Technology Company
no operation time available
4 offices
Technology Company
no operation time available
7 offices
Technology Company

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Merck Sharp & Dohme Corporation, Merck Sharp & Dohme Ltd., and Merck & Co. Inc. are specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 224 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 31.10.2008 - Priority Date (US 20080197869P)
  • 15.04.2015 - Publication A2 (EP2860178)
  • 20.05.2015 - Publication A3 (EP2860178)